ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2010

Adenosine A2A Receptor, but Not A2B Receptor, Deletion Leads to Development of Osteoarthritis (OA) in Mice and Administration of a Liposomal Suspension of Adenosine Prevents/Treats Osteoarthritis in Rats

CARMEN CORCIULO1, MATIN Lendhey2, AUSTIN RAMME2, Tuere Wilder3, ORAN KENNEDY2 and Bruce Cronstein4, 1Medicine, NYU-School of Medicine, New York, NY, 2Department of Orthopaedic Surgery, NYU-School of Medicine, New York, NY, 3Dept of Med, Div of Rheum, NYU School of Medicine, New York, NY, 4Medicine, Division of Rheumatology, NYU School of Medicine, NEW YORK, NY

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Adenosine receptors, cartilage, chondrocytes, osteoarthritis and therapy

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Biology and Pathology of Bone and Joint: Ostearthritis Pathogenesis

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Adenosine, acting at its receptors, regulates chondrocyte function and inflammation, two components of OA. Mice lacking adenosine A2A receptors (A2AR) have increasing difficulty walking as they age. We report here that A2ARKO mice have changes consistent with OA in their knees and treatment with a liposomal adenosine (lipado) suspension abrogates development of OA in a rat anterior cruciate ligament (ACL) injury model of OA.

Methods: Knee joints of WT and A2ARKO mice (n=5/group) were studied by micro-computed (µCT) analysis and immunohistochemistry. Locomotor activity in mice was measured with open-field and rotarod tests. Primary articular chondrocytes from neonatal WT or A2ARKO mice were studied for altered expression of OA markers. OA was induced in rats by mechanical rupture of ACL. Rats (n=3/group) were treated with intra-articular injection of 100µl of saline, a liposomal formulation containing adenosine (10 mg/Kg) or empty liposomes (lipo) and weight and knee swelling of the rats were monitored. Rat legs were harvested after 56 days to evaluate the joints and plasma cytokine levels were quantitated in rats, WT and A2ARKO mice. 

Results: A2ARKO mice did not move as far as WT mice (A2ARKO=664±123 cm vs WT=1404±128 cm, p<0.001); nor did they move as fast (A2ARKO=1.11±0.21 cm/sec vs WT=2.34±0.21 cm/sec, p<0.001) and fell more quickly from the rotarod apparatus (A2ARKO=86±11sec vs WT=145±22 sec, p<0.05). A2ARKO mice had progressive joint damage consistent with OA (e.g. OARSI score at 16 weeks for A2ARKO=3.7±0.6 vs WT=1.5±0.2, p<0.01). In contrast, knee joints of 19wk old A2BRKO mice did not differ from WT.  Chondrocytes isolated from neonatal A2ARKO mice, but not WT, spontaneously expressed and secreted collagen X, fibronectin, osteopontin and MMP-13. Rats treated with intra-articular lipado were significantly less swollen (difference between uninjured and injured knee was 2.32±0.07mm for saline group, 2.35±0.36mm for lipo-treated and 0.93±0.12mm for lipado-treated, p<0.01, 1-way ANOVA). Macroscopic evaluation of joints showed near-normal appearing cartilage in lipado-treated rats but pitting and loss of cartilage in saline or lipo-treated rats.  There was a marked reduction of subchondral bone changes in µCTs of lipado-treated mice as well and plasma levels of IL-1b, IL-6, IFNg, IL-5, TNFa and RANTES were significantly lower in rats treated with lipado. 

Conclusion: These findings suggest that the presence and tonic activation of A2AR in the joint are important for maintaining joint homeostasis. Moreover these results suggest that adenosine receptors may be a novel target for treatment of OA.


Disclosure: C. CORCIULO, None; M. Lendhey, None; A. RAMME, None; T. Wilder, None; O. KENNEDY, None; B. Cronstein, Bristol-Myers Squibb, 5,Novartis Pharmaceutical Corporation, 5,Canfite Pharma, 5,Revive Therapeutics, 5,Regeneron, 5,Gismo Therapeutics, 5,Antares Pharmaceuticals, 5,Canfite Pharma, 1,Gilead Pharmaceuticals, 2,AstraZeneca, 2,Takeda, 2,Celgene, 2.

To cite this abstract in AMA style:

CORCIULO C, Lendhey M, RAMME A, Wilder T, KENNEDY O, Cronstein B. Adenosine A2A Receptor, but Not A2B Receptor, Deletion Leads to Development of Osteoarthritis (OA) in Mice and Administration of a Liposomal Suspension of Adenosine Prevents/Treats Osteoarthritis in Rats [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/adenosine-a2a-receptor-but-not-a2b-receptor-deletion-leads-to-development-of-osteoarthritis-oa-in-mice-and-administration-of-a-liposomal-suspension-of-adenosine-preventstreats-osteoarthritis-in-r/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/adenosine-a2a-receptor-but-not-a2b-receptor-deletion-leads-to-development-of-osteoarthritis-oa-in-mice-and-administration-of-a-liposomal-suspension-of-adenosine-preventstreats-osteoarthritis-in-r/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology